OncoMatch/Clinical Trials/NCT06617897

Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery

Is NCT06617897 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including CSL511 Fibrinogen concentrate (human) and Cryoprecipitate for acquired fibrinogen deficiency.

Phase 3RecruitingCSL BehringNCT06617897Data as of May 2026

Treatment: CSL511 Fibrinogen concentrate (human) · Cryoprecipitate — This study is a phase 3, prospective, single center, randomized, open label, controlled, parallel arm, interventional study to investigate the efficacy and safety of CSL511, in participants undergoing cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei (PMP) with predicted intraoperative blood loss of greater than or equal to (\>=) 2 liter (L). Eligible participants will be randomized in a 1:1 ratio to 1 of 2 treatment arms, to receive CSL511 or cryoprecipitate.

Check if I qualify

Eligibility summary

For patients with pseudomyxoma peritonei.

This summary was generated by AI from the trial's official eligibility criteria and may contain errors. Always confirm with the study team before contacting a site.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify